JW (Cayman) Therapeutics Past Earnings Performance
Past criteria checks 0/6
JW (Cayman) Therapeutics has been growing earnings at an average annual rate of 0.4%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 70.6% per year.
Key information
0.4%
Earnings growth rate
42.1%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 70.6% |
| Return on equity | -45.6% |
| Net Margin | -441.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How JW (Cayman) Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 174 | -768 | 253 | 414 |
| 30 Sep 23 | 171 | -783 | 294 | 421 |
| 30 Jun 23 | 167 | -797 | 334 | 428 |
| 31 Mar 23 | 157 | -822 | 352 | 418 |
| 31 Dec 22 | 146 | -846 | 371 | 408 |
| 30 Sep 22 | 121 | -849 | 383 | 416 |
| 30 Jun 22 | 97 | -851 | 396 | 425 |
| 31 Mar 22 | 64 | -777 | 384 | 420 |
| 31 Dec 21 | 31 | -702 | 372 | 414 |
| 30 Sep 21 | 15 | -998 | 344 | 371 |
| 30 Jun 21 | -1 | -1,294 | 315 | 328 |
| 31 Mar 21 | 0 | -1,479 | 280 | 277 |
| 31 Dec 20 | 0 | -1,664 | 245 | 225 |
| 30 Sep 20 | 3 | -1,295 | 186 | 195 |
| 30 Jun 20 | 6 | -925 | 128 | 164 |
| 31 Mar 20 | 6 | -779 | 101 | 150 |
| 31 Dec 19 | 5 | -633 | 73 | 136 |
| 31 Dec 18 | 0 | -273 | 41 | 76 |
Quality Earnings: 2126 is currently unprofitable.
Growing Profit Margin: 2126 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2126 is unprofitable, but has reduced losses over the past 5 years at a rate of 0.4% per year.
Accelerating Growth: Unable to compare 2126's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2126 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 2126 has a negative Return on Equity (-45.61%), as it is currently unprofitable.